Medical Informatics World’s Fifth Annual

Pharma-ACO Data Collaboration for Healthcare Innovation

Collaborating with Providers to Enhance Outcomes in a Pay-For-Performance Landscape

pharma-collabWith the healthcare landscape shifting to value-based, pay-for-performance accountable care organizations (ACOs) and the pressure to deliver better outcomes increasing, the need for cross-industry collaboration is apparent, especially in regards to the pharmaceutical industry. More than ever before, the pharmaceutical industry is being called to actively participate in healthcare by sharing data and collaborating with ACOs. 

Cambridge Healthtech Institute and Clinical Informatics News’ Fifth Annual Pharma-ACO Data Collaboration for Healthcare Innovation conference, taking place May 22-23, 2017 at the Renaissance Waterfront Hotel in Boston, MA, will bring together leaders from pharma, payer, provider, and academic communities for innovative discussions around this topic.

Final Agenda

Monday, May 22

Day 1 | Day 2 | Download Brochure

7:00 am Registration and Morning Coffee



 John_MattisonJohn Mattison, M.D., Assistant Medical Director, CMIO, CHIO, National and Regional Leadership, Kaiser Permanente

 Andrea_IppolitoAndrea Ippolito, VA Innovators Lead, Department of Veterans Affairs Center for Innovation

 Saurabha_BhatnagarSaurabha Bhatnagar, M.D., Innovation Specialist, Medical Director TBI/Polytrauma, Harvard Medical School

 Patrick_McIntyrePatrick McIntyre, Senior Vice President, Health Care Analytics, Anthem, Inc.

 David_SheinDavid Shein, M.D., Medical Director, The Mount Auburn Cambridge Independent Practice Association (MACIPA)

View Details


10:10 Coffee Break in the Exhibit Hall with Poster Viewing


10:55 Chairperson’s Remarks

John Cai, M.D., Ph.D., Director, Medical Informatics, Information and Knowledge Utilization (IKU), Celgene

11:00 Co-Presentation: Leveraging Cross-Industry Perspectives to Generate Insights to Outcomes and Better Care Process Models

Nicole_HobbsNicole Hobbs, Ph.D., Director, Medical Informatics, Business Development, Intermountain Healthcare

Patrick_GillardPatrick Gillard, Director, Global Health Economics and Outcomes Research, Allergan

Leveraging cross-industry perspectives and electronic health record data to analyze treatment patterns and clinical outcomes can lead to insights for improved clinical care. Our organizations have partnered to better understand treatments patterns and outcomes in patients with acute bacterial skin and skin structure infections (ABSSSI). The goal of this collaboration has been to identify and characterize treatment variability and outcomes in order to enhance care process models to benefit patients, hospitals, and payers.

12:00 pm Collaborating with ACOs for Improved Quality of Care

Wayne_PanWayne Pan, Medical Director, Quality of Care, Genentech

Pharmaceutical companies have a vested interest in improving patient outcomes, and collaborating with ACOs allows those companies to gain more knowledge and insight. This talk will discuss Genentech’s collaborations and how they are using big data, design thinking, and health information technology to set up, utilize, and manage ACO collaborations for improved drug discovery and development.

Dacadoo12:30 Why Healthcare Needs a Health Score

Matt_ParkMatt Park, Vice President, Sales, dacadoo

Without a way to measure individual health in real-time, pharma companies and ACO’s will struggle to determine the true results of their value-based partnerships. Learn how this revolutionary, patented Health Score generates real-time data to measure outcomes, boost engagement and encourage positive lifestyle behavior change among patients.

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:30 Session Break


2:05 Chairperson’s Remarks

Craig Lipset, Head of Clinical Innovation, Pfizer

2:10 Collaborating with Healthcare Systems to Drive Clinical Research and Improve Patient Outcomes

Katherine_VandebeltKatherine Vandebelt, Global Head, Clinical Innovation, Eli Lilly and Company

Clinical research is necessary to bring drugs to market, but moreover it is key to gaining valuable insights into unique patient responses, which further drives drug candidate improvements and, ultimately, patient outcomes. This talk will discuss Eli Lilly’s collaborations in healthcare to drive clinical research as a care option, and how they are using that data to improve drug discovery and development.

2:20 Clinical Research as a Care Option in Moving from a Volume-Based Health System to a Value-Based Health System

Jeff_JamesJeff James, CEO, Wilmington Health

The healthcare system is rapidly moving away from volume-based payment methodologies to value based payment methodologies. Health systems that programmatically use clinical research as a care option have one additional arrow in the quiver in their pursuit of health for populations, lowering the cost of care and improving the patient experience.

2:30 PANEL DISCUSSION: Demonstrating the Value of Research Participation to Health Systems, ACOs, and Patients

Craig_LipsetCraig Lipset, Head of Clinical Innovation, Pfizer


Katherine_VandebeltKatherine Vandebelt, Global Head, Clinical Innovation, Eli Lilly and Company

Jeff_JamesJeff James, CEO, Wilmington Health

Jennifer_ByrneJennifer Byrne, Founder, The Greater Gift; Former CEO, PMG Research

Toyin_OkanlawonToyin Okanlawon, M.D., MPH, Senior Project Leader and Senior Healthcare Researcher, Institute for Strategy and Competitiveness, Harvard Business School

Many of the challenges in clinical research today may be attributed to a lack of aligned incentives. As an example, clinical trial participation rates are below 5% for urgent conditions such as Oncology. While most patients indicate being receptive to clinical research and wanting to learn of research opportunities from their healthcare provider, few treating physicians present research participation as an option for their patients. Wilmington Health, PMG Research and Lilly have generated data suggesting that patients participating in research may have improved outcomes, lower cost of care, and higher patient satisfaction – triple aims that are good for the patient as well as the supporting health system. These data create the opportunity to align incentives, and support ACOs and health systems to encourage providers to offer clinical research as a care option for all appropriate patients. This session will review existing data, and discuss pathways forward to increase research participation within the modern healthcare system.

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing


4:10 pm Find Your Table and Meet Your Moderator

4:15 Interactive Breakout Discussion Groups

Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become an active part of the discussion at hand. To get the most out of this interactive session and format, please come prepared to share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea-sharing.

View Details

5:00 - 6:00 Welcome Reception in the Exhibit Hall with Poster Viewing

6:00 Close of Day

Tuesday, May 23

Day 1 | Day 2 | Download Brochure

7:30 am Registration and Morning Coffee



 John_HalamkaJohn Halamka, M.D., MS, CIO, Beth Israel Deaconess Medical Center

 Maxine_MackintoshMaxine Mackintosh, Chair & Ph.D. Student, HealthTech Women UK & University College London

 Trishan_PanchTrishan Panch, M.D., Co-Founder and CMO, Wellframe; Lecturer, MIT

View Details

10:10 Coffee Break in the Exhibit Hall with Poster Viewing


10:55 Chairperson’s Remarks

Nirmal Keshava, Ph.D., Senior Healthcare Data Scientist, formerly AstraZeneca

11:00 Real-World Treatment Pathways for Patient Stratification

John_CaiJohn Cai, M.D., Ph.D., Director, Medical Informatics, Information and Knowledge Utilization (IKU), Celgene

Healthcare decision-making requires better understanding of the full patient journey at both individual and population levels. Real-world treatment pathways reconstructed from real-world big data will enable such real-time decision support. This presentation will answer the following related questions: 1. What are real-world treatment pathways vs. clinical pathways or clinical practice guidelines? 2. Why real-world treatment pathways, i.e., what is their role for Precision Medicine or population health management? 3. How/where do we find real-world treatment pathways, and how would real-world big data help? A real-world case study will be used to address the questions above.

11:30 Understanding Variability in Drug Response: Starting with Demographic Transparency

John_WhyteJohn Whyte, MD, MPH, Director, Professional Affairs and Stakeholder Engagement, Office of the Center Director, U.S. Food and Drug Administration

In years past, many stakeholder groups have raised questions about adequate and equal inclusion of women and people of racial minority backgrounds within clinical trials. Ensuring easy access to and unveiling of demographic data for the pivotal clinical trials used to approve new drugs, the FDA created the Drug Trial Snapshots program in November 2014. With more details on who participated in the pivotal trials and whether there were any observed differences in safety and efficacy by demographic subgroups of sex, race, and age, the Drug Trial Snapshots raise important questions about population-based drug development and variability in response to drugs overall.

12:00 pm A View from the Front Lines of Data Science in the Pharmaceutical Industry

Nirmal_KeshavaNirmal Keshava, Ph.D., Senior Healthcare Data Scientist, formerly AstraZeneca

Transforming the life sciences through data science is a work in progress and one that has tremendous possibilities but also many obstacles. In this talk, I will provide a perspective on the role of the data scientist as a change agent and I will cite specific examples of challenges that have been undertaken to enable and accelerate evidence-based, data-driven decision-making. These include developing novel, innovative, machine learning approaches using “Big Data” for population-level studies and optimizing the planning and recruitment for clinical trials using analytics. The talk will conclude by highlighting opportunities for life science organizations to create value from data science in ways that are technical, organizational, and cultural.

12:30 Clinical Trial Readiness: Big Data, Collaborations and Patient Centricity in Rare Diseases

Alex_ShermanAlex Sherman, Director, Strategic Development & Systems, Neurological Clinical Research Institute at Massachusetts General Hospital, Harvard Medical School

The collaborative patient-centered environment, methodology, processes and distributed infrastructure for creating “Big Data” in rare diseases. Large datasets are critical for identifying statistically significant and biologically relevant observations, and developing validated biomarkers and outcome measures relevant for clinical trials. Heterogeneity of many diseases complicates disease modeling and potential therapies development, making clinical trials challenging. Precision medicine has the potential to turning any diseases into a rare one. Proposed collaborative patient-centered environment, methodology, processes, and distributed infrastructure and the platform for clinical and research information aggregation and sharing allow rare diseases to enter the Age of "Big Data."

1:00 Enjoy Lunch on Your Own

1:30 Coffee and Dessert in the Exhibit Hall with Poster Viewing


Special Shared Session

2:00 Chairperson’s Remarks

Blackford Middleton, M.D., Chief Informatics & Innovation Officer, Apervita, Inc., Past Chairman of the Board, American Medical Informatics Association (AMIA)

2:05 The Future of Interoperability…Trends and Practical Advice

Micky_TripathiMicky Tripathi, Ph.D., President and CEO, Massachusetts eHealth Collaborative (MAeHC)

Interoperability is likely going to surge in the next couple of years. With MIPS/MACRA laying out a roadmap for value-based payment models, there will be provider demand for interoperability to improve care delivery as well as for broader population health goals. The private sector is starting to deliver on the promise of health exchange with the growth of the CommonWell and Carequality nationwide record-sharing initiatives, and the maturation of FHIR-based solutions. Providers may soon go from having not enough interoperability solutions to having a bewildering array of choices. This talk will describe these trends and offer practical advice for those trying to develop health information exchange strategies.

2:35 HL7 FHIR: Transforming Biomedical Interoperability

Charles_JaffeCharles Jaffe, M.D., Ph.D., CEO, Health Level Seven (HL7)

HL7 FHIR has become the true promise of biomedical Interoperability. As a normative standard, now adopted worldwide, FHIR applications have transformed the means by which data is shared for patient care, biomedical research, population health, precision medicine, and even payment systems. The FHIR platform has sped application development times, reduced costs, enabled ISO-standard authentication and authorization technologies, and improved integrated care delivery. FHIR is fast becoming the DNA of data interoperability.

3:05 Understanding Requirements for Research Informatics to Support a Learning Health System

Rebecca_KushRebecca Kush, Ph.D., President and Founder, CDISC

This is a critical time for the healthcare provider, clinical research and biopharmaceutical industry communities to understand requirements, hurdles and opportunities for research informatics to support a Learning Health System, which plays a key role in the strategic plan of the HHS/ONC. Healthcare Link’s goals are to: make it easier for physicians to conduct clinical research, collect data only once in an industry standard format for multiple downstream uses, and improve data quality and patient safety.

3:20 INTERACTIVE PANEL: The Current State and Future of Healthcare Information Exchange and Interoperability: Action Items for Today and Tomorrow

Nick_van_TerheydenNick van Terheyden, M.D., Chief Medical Officer, NTT DATA, Inc.



Charles Jaffe, M.D., Ph.D., CEO, HL7


Micky Tripathi, Ph.D., President and CEO, Massachusetts eHealth Collaborative (MAeHC)


Greg Moody, Director, Governor’s Office of Health Transformation, State of Ohio

Rebecca_KushRebecca Kush, Ph.D., President and Founder, CDISC

In today’s rapidly changing healthcare landscape, it is more important than ever for information to be shared in a very timely manner; both patient and process centric. The investment in interoperability provided by ARRA/HITECH has only been able to go so far in the establishment of the requirements/structure for the information to be appropriately and securely shared. In the absence of one established method and/or process, several approaches are moving forward to fill the void; EMRs, FHIR, HIEs, etc. Do these approaches compete or complement each other? Topics to be discussed include:

  • How do you believe that ARRA/HITECH/MU has helped or hindered interoperability?
  • Do you believe there is one method that we should consider for secure data sharing or is there room for different approaches?
  • Do you believe that the secure sharing of patient records can be legislated into being or is this something that should be accomplished in concert with the private sector?

4:05 Closing Remarks

5:00 - 7:00 Join Bio-IT World’s Grand Opening Reception in the Bio-IT World Exhibit Hall at the Seaport World Trade Center

Day 1 | Day 2 | Download Brochure